FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, immunology and microbiology, in particular to mRNA-based vectors containing certain 5'- and 3'-non-translated regions for increased production of the target protein, as well as to a method for using the said vectors for the synthesis of the target protein in cells mammals.
EFFECT: invention provides for the creation of an mRNA-based vector that is stable and provides increased levels of target protein production, such as a vaccine antigen, antibody, therapeutic protein or enzyme.
8 cl, 7 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOBIOLOGICAL AGENT FOR INDUCING A COMPLEX IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS AND INFLUENZA VIRUS AND USE THEREOF | 2024 |
|
RU2836687C1 |
| PLASMID DNA CARTRIDGE pVAX-C3-polyA, PLASMID DNA MATRIX pVAX-C3-RBD-polyA FOR mRNA SYNTHESIS AND POLYNUCLEOTIDE VACCINE AGAINST SARS-CoV-2, WHICH IS MOLECULES mRNA-C3-RBD-polyA WHICH INDUCE SARS-CoV-2-SPECIFIC ANTIBODIES | 2024 |
|
RU2839841C1 |
| PLASMID DNA MATRIX AND mRNA MOLECULE USED TO PRODUCE VACCINE AGAINST CORONAVIRUS, OBTAINED USING DNA MATRIX AND PROVIDING EXPRESSION OF GENE OF ARTIFICIAL POLYEPITOPIC PROTEIN-IMMUNOGEN CONTAINING CONSERVED EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC IMMUNITY | 2024 |
|
RU2839372C1 |
| CATIONIC LIPID FOR DELIVERY OF NUCLEIC ACIDS INTO MAMMALIAN CELLS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2024 |
|
RU2836309C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| HEAVY-CHAIN MONOCLONAL ANTIBODIES SPECIFICALLY BINDING TO S PROTEIN OF SARS-CoV-2 VIRUS, AND METHOD OF USING THEM FOR TREATMENT OF DISEASES CAUSED BY DIFFERENT VARIANTS OF SARS-CoV-2 VIRUS | 2024 |
|
RU2836313C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS AND METHOD OF ITS USE FOR EMERGENCY PREVENTION AND PROPHYLAXIS OF DISEASES CAUSED BY SARS-CoV-2 VIRUS (VERSIONS) | 2022 |
|
RU2777404C1 |
| NUCLEIC ACID CONTAINING REGULATORY ELEMENTS TPL, AES AND mtRNR1 | 2023 |
|
RU2831163C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
